Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC
World Journal of Urology · 2023
DOI: 10.1007/s00345-023-04583-w ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Urology, 2023. Verfasst von Ninni Mu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Circulating Tumor DNA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Region Stockholm, Japanese Swedish Research Foundation, Barncancerfonden.
Abstract (Originalsprache)
Purpose
The prognosis of upper urinary tract urothelial carcinoma (UTUC) is associated with tumour grade (G) and stage. Despite preoperative risk stratification and radical treatment, recurrence and progression are common. Thus, prognostic and monitoring biomarkers are needed. This feasibility study aimed to investigate if targeted analyses on circulating tumour DNA (ctDNA) in plasma could identify tumour-specific gene variants, and thus have potential for further evaluation as a biomarker in UTUC.
Methods
Nine UTUC patients with genetically characterised tumours were included in this prospective pilot study. Two tumour-specific variants were chosen for targeted analyses with multiplex droplet digital PCR on cell-free DNA (cfDNA) from plasma at diagnosis or from recurrence.
Results
Of six patients with diagnostic plasma samples, ctDNA was detected in four with G2 or G3 tumours and tumours > 300m 2 in size. Three of these patients progressed in their disease and the fourth had the largest G3 tumour at sampling. In contrast, the two patients with undetectable ctDNA in diagnostic plasma had a G1 tumour and G3 carcinoma in situ (CIS), respectively. The patient with G3 CIS had detectable ctDNA later during follow-up and progressed thereafter with aggressive intravesical recurrence and CT-scan-verified CIS progression in the upper urinary tract. In three patients with small recurrent G1 or G2 tumours, none had detectable ctDNA in plasma and all were progression free.
Conclusion
Our early findings demonstrate that ctDNA in plasma can be detected by targeted analysis in patients with UTUC. However, further studies are needed to determine its role as a potential biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
- Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.
- Division of Urology, Danderyd Hospital, Stockholm, Sweden.
- Department of Urology, Stockholm South General Hospital, Stockholm, Sweden.
- Department of Clinical Sciences, Karolinska Institutet, Stockholm, Sweden.
Förderung
- Region Stockholm
- Japanese Swedish Research Foundation
- Barncancerfonden
- Cancerfonden
- Stiftelsen Johanna Hagstrand och Sigfrid Linnérs Minne
- Karolinska Institute
Zitieren
APA
Mu, N., Jylhä, C., Axelsson, T., Sydén, F., Brehmer, M., & Tham, E. (2023). Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC. World Journal of Urology. https://doi.org/10.1007/s00345-023-04583-w
Vancouver
Mu N, Jylhä C, Axelsson T, Sydén F, Brehmer M, Tham E. Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC. World Journal of Urology. 2023. doi:10.1007/s00345-023-04583-w
BibTeX
@article{Mu2023,
author = {Mu, Ninni and Jylhä, Cecilia and Axelsson, Tomas and Sydén, Filip and Brehmer, Marianne and Tham, Emma},
title = {Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC},
journal = {World Journal of Urology},
year = {2023},
doi = {10.1007/s00345-023-04583-w}
}
EUVIMED